Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05112939 · ClinicalTrials.gov registry record · Phase 1
A Study of a Rilpivirine Extended-Release Suspension in Healthy Participants
A Phase 1 study, sponsored by Janssen Research & Development.
- Completed
- Registry status
- Phase 1
- Development phase
- 126
- Enrollment target
NCT05112939: Completed Phase 1 study, sponsored by Janssen Research & Development.
NCT05112939 is a Phase 1 study that has completed, run by Janssen Research & Development. The registered enrollment target is 126 participants, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (110% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05112939, a Phase 1 study, has completed, sponsored by Janssen Research & Development.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 126 participants
- Enrollment target
Study Summary
The purpose of this study is to characterize the single dose pharmacokinetics (PK) and evaluate the safety and tolerability of subcutaneous administration of rilpivirine (RPV) long-acting (LA) or RPV LA in combination with cabotegravir (CAB) LA extended release suspensions in different conditions in healthy adult participants.
Primary Outcome
Plasma samples will be analyzed to determine concentrations of RPV using a validated, specific, and sensitive method.
Interventions
- DRUG CAB LA
- DRUG RPV LA
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 126 participants |
| Start Date | 2021-11-16 |
| Est. Completion | 2024-05-23 |
| Phase | Phase 1 |
What the finished NCT05112939 record still lists
NCT05112939 is an interventional study that assigns participants to a tested intervention. The registered 126 participants enrollment target is mid-sized for trials with a published cap, above the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (110% higher).
The record links to 0 conditions, and to 2 interventions - of which CAB LA is the first listed.
NCT05112939 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT05112939 about?
NCT05112939 is a clinical study titled "A Study of a Rilpivirine Extended-Release Suspension in Healthy Participants". The purpose of this study is to characterize the single dose pharmacokinetics (PK) and evaluate the safety and tolerability of subcutaneous administration of rilpivirine (RPV) long-acting (LA) or RPV LA in combination with cabotegravir (CAB) LA extended release suspensions in different conditions in...
What is the current status of trial NCT05112939?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 126 participants. The study started on 2021-11-16. Estimated completion is 2024-05-23.
What interventions are being tested in trial NCT05112939?
The interventions under investigation include: CAB LA (DRUG), RPV LA (DRUG).
Who is sponsoring clinical trial NCT05112939?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT05112939's enrollment target sits among peer trials
126 461st of 2000 higher than 1,534 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01873131 · 126 participants · NA
A Clinical Trial of Pulsed-dye Laser Versus Timolol Topical Solution Versus Observation on the Growth of Hemangioma in Newborn
- NCT02621645 · 126 participants · Phase 4
TRAP Intervention STudy: Early Versus Late Intervention for Twin Reversed Arterial Perfusion Sequence
- NCT03838107 · 126 participants
Markers of Trajectory in Pediatric CRPS
- NCT03906422 · 126 participants · NA
Comparison of Patient-reported Pain After Initial Archwire Placement
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI